1. Younossi, Z.M., et al., The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clinical Gastroenterology and Hepatology, 2024. 22(10): p. 1999–2010. e8.. DOI: 10.1016/j.cgh.2024.03.006 2. Spremović Rađenović, S., et al., Prevalence, risk factors, and pathophysiology of nonalcoholic fatty liver disease (NAFLD) in women with polycystic ovary syndrome (PCOS). Biomedicines, 2022. 10(1): p. 131.. DOI: 10.3390/biomedicines10010131 3. Semmler, G., et al., Diet and exercise in NAFLD/NASH: beyond the obvious. Liver International, 2021. 41(10): p. 2249–2268.. DOI: 10.1111/liv.15024 4. Zhang, C.-K., Z.-Z. Wang, and F.-H. Li, Long-term aerobic exercise enhances liver health: miRNA regulation and oxidative stress alleviation. Biochemical and Biophysical Research Communications, 2025. 759: p. 151677.. DOI: 10.1016/j.bbrc.2025.151677 5. Zou, Y., et al., Transcriptomic profiling of long non-coding RNAs and messenger RNAs in the liver of mice during Toxoplasma gondii infection. Parasites & vectors, 2024. 17(1): p. 20.. DOI: 10.1186/s13071-023-06053-z 6. Abubakar, M., et al., Non-coding RNA-mediated gene regulation in cardiovascular disorders: current insights and future directions. Journal of Cardiovascular Translational Research, 2024. 17(4): p. 739–767. DOI: 10.1007/s12265-023-10469-4. 7. Shin, J.-J., et al., Roles of lncRNAs in NF-κB-Mediated macrophage inflammation and their implications in the pathogenesis of human diseases. International Journal of Molecular Sciences, 2024. 25(5): p. 2670. DOI: 10.3390/ijms25052670. 8. Li, C., et al., Regulatory mechanisms of long non-coding RNAs on mitochondrial function in congestive heart failure. Non-coding RNA Research, 2024. 9(1): p. 178–184.. DOI: 10.1016/j.ncrna.2023.11.007 9. Wu, B., et al., Aerobic exercise promotes the expression of ATGL and attenuates inflammation to improve hepatic steatosis via lncRNA SRA. Scientific Reports, 2022. 12(1): p. 5370..DOI: 10.1038/s41598-022-09174-0 10. Varabyou, A., S.L. Salzberg, and M. Pertea, Effects of transcriptional noise on estimates of gene and transcript expression in RNA sequencing experiments. Genome research, 2021. 31(2): p. 301–308..DOI: 10.1101/gr.266213.120 11. Klapproth, C., et al., Common features in lncRNA annotation and classification: a survey. Non-coding RNA, 2021. 7(4): p. 77. DOI: 10.3390/ncrna7040077 12. Mattick, J.S., et al., Long non-coding RNAs: definitions, functions, challenges and recommendations. Nature reviews Molecular cell biology, 2023. 24(6): p. 430–447.. DOI: 10.1038/s41580-022-00566-8 13. Statello, L., et al., Gene regulation by long non-coding RNAs and its biological functions. Nature reviews Molecular cell biology, 2021. 22(2): p. 96–118.. DOI: 10.1038/s41580-020-00315-9 14. Studniarek, C., S. Egloff, and S. Murphy, Noncoding RNAs set the stage for RNA polymerase II transcription. Trends in Genetics, 2021. 37(3): p. 279–291. DOI: 10.1016/j.tig.2020.09.013 15. Pisignano, G. and M. Ladomery, Post-transcriptional regulation through long non-coding rnas (lncrnas). 2021, MDPI. p. 29.. DOI: 10.3390/ncrna7020029 16. Grammatikakis, I. and A. Lal, Significance of lncRNA abundance to function. Mammalian Genome, 2022. 33(2): p. 271–280. DOI: 10.1007/s00335-021-09901-4 17. Zhang, S., et al., Screening of bovine tissue-specific expressed genes and identification of genetic variation within an adipose tissue-specific lncRNA gene. Frontiers in Veterinary Science, 2022. 9: p. 887520.. DOI: 10.3389/fvets.2022.887520 18. Camilleri-Robles, C., et al., Genomic and functional conservation of lncRNAs: lessons from flies. Mammalian Genome, 2022. 33(2): p. 328–342.. DOI: 10.1007/s00335-021-09939-4 19. Brandt, A. and F. Kopp, Long Noncoding RNAs in Diet-Induced Metabolic Diseases. International Journal of Molecular Sciences, 2024. 25(11): p. 5678.. DOI: 10.3390/ijms25115678 20. Ji, M., et al., Naringenin prevents oxidative stress and inflammation in LPS-induced liver injury through the regulation of LncRNA-mRNA in male mice. Molecules, 2022. 28(1): p. 198..DOI: 10.3390/molecules28010198 21. Zhu, S.-F., et al., Research progress of lncRNA and miRNA in hepatic ischemia-reperfusion injury. Hepatobiliary & Pancreatic Diseases International, 2023. 22(1): p. 45–53..DOI: 10.1016/j.hbpd.2022.07.008 22. Zou, D., et al., LncRNA MEG3 up-regulates SIRT6 by ubiquitinating EZH2 and alleviates nonalcoholic fatty liver disease. Cell Death Discovery, 2022. 8(1): p. 103.. DOI: 10.1038/s41420-022-00889-7 23. Moradzad, M., et al., TMAO promotes metabolic dysfunction-associated fatty liver disease (MAFLD) development through long-non coding RNA-highly upregulated liver cancer (HULC). Journal of Diabetes & Metabolic Disorders, 2025. 24(1): p. 1–11.. DOI: 10.1007/s40200-025-01605-9 24. Shi, N., et al., The impact and role of identified long noncoding RNAs in nonalcoholic fatty liver disease: A narrative review. Journal of Clinical Laboratory Analysis, 2023. 37(11-12): p. e24943..DOI: 10.1002/jcla.24943 25. Mukherjee, A.G., et al., Exploring the regulatory role of ncRNA in NAFLD: a particular focus on PPARs. Cells, 2022. 11(24): p. 3959.. DOI: 10.3390/cells11243959 26. Fei, Q., et al., The Impact of Aerobic and Anaerobic Exercise Interventions on the Management and Outcomes of Non-Alcoholic Fatty Liver Disease. Physiological Research, 2024. 73(5): p. 671.. DOI: 10.33549/physiolres.935244 27. Zhang, Y., et al., Long-Term Aerobic Exercise Enhances Hepatoprotection in MAFLD by Modulating Exosomal miR-324 via ROCK1. Metabolites, 2024. 14(12): p. 692.. DOI: 10.3390/metabo14120692 28. Hu, J., X. Miao, and L.-H. Yu, Long Non-Coding RNAs in Diabetic Cardiomyopathy: Potential Function as Biomarkers and Therapeutic Targets of Exercise Training. Journal of Cardiovascular Translational Research, 2025: p. 1–17.. DOI: 10.1007/s12265-024-10586-8 29. Pino-de la Fuente, F., et al., Exercise regulation of hepatic lipid droplet metabolism. Life Sciences, 2022. 298: p. 120522.. DOI: 10.1016/j.lfs.2022.120522 30. Shen, Z., et al., Prediction of Back-splicing sites for CircRNA formation based on convolutional neural networks. BMC genomics, 2022. 23(1): p. 581. DOI: 10.1186/s12864-022-08820-1. 31. Wang, P., et al., The function and regulation network mechanism of circRNA in liver diseases. Cancer Cell International, 2022. 22(1): p. 141.. DOI: 10.1186/s12935-022-02559-1 32. Yang, L., J.E. Wilusz, and L.-L. Chen, Biogenesis and regulatory roles of circular RNAs. Annual review of cell and developmental biology, 2022. 38(1): p. 263–289.. DOI: 10.1146/annurev-cellbio-120420-125117 33. Chodurska, B. and T. Kunej, Long Non-Coding RNAs in Humans: Classification, Genomic Organization and Function. Non-coding RNA Research, 2025.. DOI: 10.1016/j.ncrna.2025.01.004 34. Ma, B., et al., Mechanisms of circRNA/lncRNA-miRNA interactions and applications in disease and drug research. Biomedicine & Pharmacotherapy, 2023. 162: p. 114672.. DOI: 10.1016/j.biopha.2023.114672 35. Zheng, S., et al., CircRNA—protein interactions in muscle development and diseases. International journal of molecular sciences, 2021. 22(6): p. 3262.. DOI: 10.3390/ijms22063262 36. Zheng, M., et al., Expression profile and N6-methyadenosine modification of circular RNA analysis in MAFLD. BMC gastroenterology, 2025. 25(1): p. 162.. DOI: 10.1186/s12876-025-03722-4 37. Yepmo, M., et al., Discussing the role of circular RNA in the pathogenesis of non-alcoholic fatty liver disease and its complications. Frontiers in Endocrinology, 2022. 13: p. 1035159..DOI: 10.3389/fendo.2022.1035159 38. Li, L.-P., et al., Oxidative stress-induced circSOD2 inhibits osteogenesis through sponging miR-29b in metabolic-associated fatty liver disease. World Journal of Gastroenterology, 2025. 31(9): p. 98027.. DOI: 10.3748/wjg.v31.i9.98027 39. Qian, G. and N. Morral, Role of non-coding RNAs on liver metabolism and NAFLD pathogenesis. Human molecular genetics, 2022. 31(R1): p. R4–R21.. DOI: 10.1093/hmg/ddac088 40. Cao, J., et al., Identification of mitochondrial function and programmed cell death associated key biomarkers and the circRNA-miRNA-mRNA regulatory network in systemic lupus erythematosus. Frontiers in Molecular Biosciences, 2025. 12: p. 1586294.. DOI: 10.3389/fmolb.2025.1586294 41. Wang, Y., et al., A read-through circular RNA RCRIN inhibits metabolic dysfunction-associated steatotic liver disease. Journal of Hepatology, 2025. 82(6): p. 1068–1079. DOI: 10.1016/j.jhep.2024.11.052 42. Zeng, Q., et al., Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance. RNA biology, 2024. 21(1): p. 65–79. DOI: 10.1080/15476286.2023.2290769 43. Shao, J., et al., Interference of a mammalian circRNA regulates lipid metabolism reprogramming by targeting miR-24-3p/Igf2/PI3K-AKT-mTOR and Igf2bp2/Ucp1 axis. Cellular and Molecular Life Sciences, 2023. 80(9): p. 252. DOI: 10.1007/s00018-023-04899-1 44. Wang, L., et al., Exercise-induced circular RNA circUtrn is required for cardiac physiological hypertrophy and prevents myocardial ischaemia–reperfusion injury. Cardiovascular research, 2023. 119(16): p. 2638–2652.. DOI: 10.1093/cvr/cvad161 45. Zaiou, M., Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease. World journal of gastroenterology, 2022. 28(35): p. 5111.. DOI: 10.3748/wjg.v28.i35.5111 46. Yu, G., et al., Circular RNAs: Rising stars in lipid metabolism and lipid disorders. Journal of cellular physiology, 2021. 236(7): p. 4797–4806.. DOI: 10.1002/jcp.30200 47. Zhong, G., Y. Lin, and Z. Huang, Identification of a novel circRNA–miRNA–mRNA regulatory axis in hepatocellular carcinoma based on bioinformatics analysis. Scientific reports, 2023. 13(1): p. 3728.. DOI: 10.1038/s41598-023-30567-2 48. Chen, L.-L. and V.N. Kim, Small and long non-coding RNAs: Past, present, and future. Cell, 2024. 187(23): p. 6451–6485.. DOI: 10.1016/j.cell.2024.10.024 49. Joshi, M., et al., Small RNAs, spermatogenesis, and male infertility: a decade of retrospect. Reproductive Biology and Endocrinology, 2023. 21(1): p. 106.. DOI: 10.1186/s12958-023-01155-w 50. Iwakawa, H.-o. and Y. Tomari, Life of RISC: Formation, action, and degradation of RNA-induced silencing complex. Molecular cell, 2022. 82(1): p. 30–43.. DOI: 10.1016/j.molcel.2021.11.026 51. Kim, H., Y.-Y. Lee, and V.N. Kim, The biogenesis and regulation of animal microRNAs. Nature Reviews Molecular Cell Biology, 2025. 26(4): p. 276–296.. DOI: 10.1038/s41580-024-00805-0 52. Zheng, H., et al., A computational modeling of pri-miRNA expression. Plos one, 2024. 19(1): p. e0290768.. DOI: 10.1371/journal.pone.0290768 53 Khadgi, B. and Y. Nam, Effects of METTL3-METTL14 on primary microRNA processing by Drosha- DGCR8. bioRxiv, 2024: p. 2024.10. 15.618347.. DOI: 10.1101/2024.10.15.618347 54. Li, H., et al., Prognostic significance of exportin-5 in hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2024. 16(7): p. 3069.. DOI: 10.4251/wjgo.v16.i7.3069 55. Goel, H. and A. Goel, MicroRNA and Rare Human Diseases. Genes, 2024. 15(10): p. 1243. 56. Liu, F., et al., Long non-coding RNA SNHG6 couples cholesterol sensing with mTORC1 activation in hepatocellular carcinoma. Nature metabolism, 2022. 4(8): p. 1022–1040. DOI: 10.1038/s42255-022-00616-7 57. Zhu, Y., et al., Therapeutic effects of microRNAs on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review and meta-analysis. International journal of molecular sciences, 2023. 24(11): p. 9168.. DOI: 10.3390/ijms24119168 58. Tobaruela-Resola, A.L., et al., Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessment. Journal of physiology and biochemistry, 2024: p. 1–14.. DOI: 10.1007/s13105-024-01037- 59. Shan, W., et al., Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease. Cell death & disease, 2015. 6(7): p. e1833–e1833.. DOI: 10.1038/cddis.2015.196 60. Latief, U., et al., Micro RNAs as emerging therapeutic targets in liver diseases. Current Protein and Peptide Science, 2022. 23(6): p. 369–383.. DOI: 10.2174/1389203723666220721122240 61. Guo, X., et al., MiRNA-122 contributes to the effect of exercise on non-alcoholic fatty liver. Chinese Journal of Tissue Engineering Research, 2024. 28(2): p. 272.. doi: 10.12307/2023.475 62. Delfan, M., et al., High-intensity interval training improves cardiac function by miR-206 dependent HSP60 induction in diabetic rats. Frontiers in Cardiovascular Medicine, 2022. 9: p. 927956..DOI: 10.3389/fcvm.2022.927956 63. Dos Santos, J.A.C., et al., Physical exercise and the functions of microRNAs. Life sciences, 2022. 304: p. 120723.. DOI: 10.1016/j.lfs.2022.120723 64. Panico, A., et al., The influence of lifestyle factors on miRNA expression and signal pathways: a review. Epigenomics, 2021. 13(2): p. 145–164.. DOI: 10.2217/epi-2020- 289 65. Elazazy, O., et al., Long non-coding RNAs and rheumatoid arthritis: pathogenesis and clinical implications. Pathology-Research and Practice, 2023. 246: p. 154512.. DOI: 10.1016/j.prp.2023.154512 66. Tang, Z., et al., The role of competing endogenous RNA network in the development of hepatocellular carcinoma: potential therapeutic targets. Frontiers in Cell and Developmental Biology, 2024. 12: p. 1341999. DOI: 10.3389/fcell.2024.1341999 67. Zeng, Q., et al., LncRNA and circRNA in patients with non-alcoholic fatty liver disease: a systematic review. Biomolecules, 2023. 13(3): p. 560.. DOI: 10.3390/biom13030560 68. Yonis, N., et al., Cracking the code: lncRNA-miRNA-mRNA integrated network analysis unveiling lncRNAs as promising non-invasive NAFLD biomarkers toward precision diagnosis. Computational Biology and Chemistry, 2025. 115: p. 108325.. DOI: 10.1016/j.compbiolchem.2024.108325 69. Zaiou, M., Peroxisome proliferator-activated receptor-γ as a target and regulator of epigenetic mechanisms in nonalcoholic fatty liver disease. Cells, 2023. 12(8): p. 1205. DOI: 10.3390/cells12081205 70. Shabgah, A.G., et al., A comprehensive review of long non-coding RNAs in the pathogenesis and development of non-alcoholic fatty liver disease. Nutrition & Metabolism, 2021. 18(1): p. 22. DOI: 10.1186/s12986-021-00552-5 71. Zeng, X., et al., Circular RNA as an epigenetic regulator in chronic liver diseases. Cells, 2021. 10(8): p. 1945.. DOI: 10.3390/cells10081945 72. Wang, S., J. Li, and Y. Zhao, Construction and analysis of a network of exercise-induced mitochondria-related non-coding RNA in the regulation of diabetic cardiomyopathy. Plos one, 2024. 19(3): p. e0297848.. DOI: 10.1371/journal.pone.0297848 73. Zhao, W., et al., Exercise improves endothelial function via the lncRNA MALAT1/miR‐320a axis in obese children and adolescents. Cardiology Research and Practice, 2021. 2021(1): p. 8840698.. DOI: 10.1155/2021/8840698 74. Ramezani, M., et al., A crosstalk between epigenetic modulations and non-alcoholic fatty liver disease progression. Pathology-Research and Practice, 2023. 251: p. 154809.. DOI: 10.1016/j.prp.2023.154809 75. Yoshitomi, R., et al., Regulatory effect of epigallocatechin-3-O-gallate on circular RNA expression in mouse liver. The Journal of Nutritional Biochemistry, 2024. 124: p. 109506.. DOI: 10.1016/j.jnutbio. 023.109506 76. Wu, L.-F., et al., Circular RNA RRM2 alleviates metabolic dysfunction-associated steatotic liver disease by targeting miR-142-5p to increase NRG1 expression. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2024. 327(4): p. G485–G498.. DOI: 10.1152/ajpgi.00255.2023 77. Yang, Y.-b., et al., Identification of a Novel Ferroptosis‐Related Gene Prediction Model for Clinical Prognosis and Immunotherapy of Colorectal Cancer. Disease Markers, 2021. 2021(1): p. 4846683..DOI: 10.1155/2021/4846683 78. Hochreuter, M.Y., et al., MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. Molecular metabolism, 2022. 65: p. 101581.. DOI: 10.1016/j.molmet.2022.101581 79. Tang, S., Y. Geng, and Q. Lin, The role of mitophagy in metabolic diseases and its exercise intervention. Frontiers in Physiology, 2024. 15: p. 1339128.. DOI: 10.3389/fphys.2024.1339128 80. Ferro, A., et al., Extracellular vesicles as delivery vehicles for non-coding RNAs: potential biomarkers for chronic liver diseases. Biomolecules, 2024. 14(3): p. 277.. DOI: 10.3390/biom14030277 81. Tang, Q. and A. Khvorova, RNAi-based drug design: considerations and future directions. Nature Reviews Drug Discovery, 2024. 23(5): p. 341–364.. DOI: 10.1038/s41573-024-00912-9 82. Cao, X., et al., ncRNADrug: a database for validated and predicted ncRNAs associated with drug resistance and targeted by drugs. Nucleic Acids Research, 2024. 52(D1): p. D1393–D1399..DOI: 10.1093/nar/gkad1042 83. Suksangrat, T., P. Phannasil, and S. Jitrapakdee, miRNA regulation of glucose and lipid metabolism in relation to diabetes and non-alcoholic fatty liver disease. Reviews on biomarker studies of metabolic and metabolism-related disorders, 2019: p. 129–148.. DOI: 10.1007/978-3-030-12668-1_7 84. Atic, A.I., et al., Circulating miRNAs associated with nonalcoholic fatty liver disease. American Journal of Physiology-Cell Physiology, 2023. 324(2): p. C588–C602. DOI: 10.1152/ajpcell.00253.2022 85. Aghaei, S.M. and S.M. Hosseini, Inflammation-related miRNAs in obesity, CVD, and NAFLD. Cytokine, 2024. 182: p. 156724.. DOI: 10.1016/j.cyto.2024.156724 86. Anwar, A.A., N. Jalan-Sakrikar, and R.C. Huebert. LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology. in Seminars in liver disease. 2024. Thieme Medical Publishers, Inc. • DOI: 10.1055/a-2490-1921 87. Wade, H., et al., Mechanistic role of long non-coding RNAs in the pathogenesis of metabolic dysfunction-associated steatotic liver disease and fibrosis. eGastroenterology, 2024. 2(4).. DOI: 10.1136/egastro-2024-100115 88. Xie, Y., et al., Profile analysis and functional modeling identify circular RNAs in nonalcoholic fatty liver disease as regulators of hepatic lipid metabolism. Frontiers in Genetics, 2022. 13: p. 884037.. DOI: 10.3389/fgene.2022.884037 89. Zhang, J., et al., The effects of exercise on epigenetic modifications: focus on DNA methylation, histone modifications and non-coding RNAs. Human Cell, 2024. 37(4): p. 887–903.. DOI: 10.1007/s13577-024-01057-y 90. Qin, F., et al., The effects of exercise on microRNA expression profiling in adipose tissue macrophages of mice. Frontiers in Immunology, 2024. 15: p. 1412621.. DOI: 10.3389/fimmu.2024.1412621 91. Soltanieh, S.K., et al., Long Non-Coding RNAs in Non-Alcoholic Fatty Liver Disease; Friends or Foes? Cell Biochemistry and Biophysics, 2025. 83(1): p. 279–294.. DOI: 10.1007/s12013-024-01555-8 92. Ma, X., et al., Physical exercise: a promising treatment against organ fibrosis. International Journal of Molecular Sciences, 2025. 26(1): p. 343.. DOI: 10.3390/ijms26010343 93. Lou, J., et al., Exercise promotes angiogenesis by enhancing endothelial cell fatty acid utilization via liver-derived extracellular vesicle miR-122-5p. Journal of Sport and Health Science, 2022. 11(4): p. 495–508.. DOI: 10.1016/j.jshs.2021.09.009 94. Wu, B., et al., Aerobic exercise improves hepatic steatosis by modulating miR-34a-mediated PPARα/SIRT1-AMPK signaling pathway. 2023.. DOI: 10.1371/journal.pone.0333872 95. Marroncini, G., et al., Gut–liver–pancreas axis crosstalk in health and disease: from the role of microbial metabolites to innovative microbiota manipulating strategies. Biomedicines, 2024. 12(7): p. 1398.. DOI: 10.3390/biomedicines12071398 96. Jiang, C., et al., Comparative transcriptomics analyses in livers of mice, humans, and humanized mice define human-specific gene networks. Cells, 2020. 9(12): p. 2566.. DOI: 10.3390/cells9122566 97. Huppertz, I. and A.C. Mullen, Function Over Form: Defining Evolutionarily Conserved Long Noncoding RNAs Regulating Hepatic Metabolism. Gastroenterology, 2025. DOI: 10.1053/j.gastro.2025.04.008. 98. Zhang, Y., et al., Protective effect of exercise on metabolic dysfunction-associated fatty liver disease: Potential epigenetic mechanisms. International Journal of Molecular Medicine, 2025. 56(4): p. 146. DOI: 10.3892/ijmm.2025.5587